These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31265333)

  • 1. Challenges in the development of egg-independent vaccines for influenza.
    Trombetta CM; Marchi S; Manini I; Lazzeri G; Montomoli E
    Expert Rev Vaccines; 2019 Jul; 18(7):737-750. PubMed ID: 31265333
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines.
    Shin D; Park KJ; Lee H; Cho EY; Kim MS; Hwang MH; Kim SI; Ahn DH
    Virus Res; 2015 Jun; 204():40-6. PubMed ID: 25892718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing.
    Trombetta CM; Marchi S; Montomoli E
    Expert Rev Vaccines; 2022 Sep; 21(9):1233-1242. PubMed ID: 35678205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging cell culture manufacturing technologies for influenza vaccines.
    Milián E; Kamen AA
    Biomed Res Int; 2015; 2015():504831. PubMed ID: 25815321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections.
    Tseng YC; Wu CY; Liu ML; Chen TH; Chiang WL; Yu YH; Jan JT; Lin KI; Wong CH; Ma C
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4200-4205. PubMed ID: 30782805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Platforms for the Development of a Universal Influenza Vaccine.
    Kumar A; Meldgaard TS; Bertholet S
    Front Immunol; 2018; 9():600. PubMed ID: 29628926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza Plasmid DNA Vaccines: Progress and Prospects.
    Bicho D; Queiroz JA; Tomaz CT
    Curr Gene Ther; 2015; 15(6):541-9. PubMed ID: 26415574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
    Venereo-Sanchez A; Gilbert R; Simoneau M; Caron A; Chahal P; Chen W; Ansorge S; Li X; Henry O; Kamen A
    Vaccine; 2016 Jun; 34(29):3371-80. PubMed ID: 27155499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of cell culture-based influenza vaccine production.
    Perdue ML; Arnold F; Li S; Donabedian A; Cioce V; Warf T; Huebner R
    Expert Rev Vaccines; 2011 Aug; 10(8):1183-94. PubMed ID: 21854311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.
    Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL
    Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccines: a main problem in control of pandemics.
    Ghendon Y
    Eur J Epidemiol; 1994 Aug; 10(4):485-6. PubMed ID: 7843363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress on baculovirus-derived influenza vaccines.
    Cox MM
    Curr Opin Mol Ther; 2008 Feb; 10(1):56-61. PubMed ID: 18228182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.
    Frey S; Vesikari T; Szymczakiewicz-Multanowska A; Lattanzi M; Izu A; Groth N; Holmes S
    Clin Infect Dis; 2010 Nov; 51(9):997-1004. PubMed ID: 20868284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of Making Effective Influenza Vaccines.
    Gouma S; Anderson EM; Hensley SE
    Annu Rev Virol; 2020 Sep; 7(1):495-512. PubMed ID: 32392457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza vaccines: new developments.
    Rimmelzwaan GF; Osterhaust AD
    Curr Opin Pharmacol; 2001 Oct; 1(5):491-6. PubMed ID: 11764775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza vaccines.
    Webby RJ; Sandbulte MR
    Front Biosci; 2008 May; 13():4912-24. PubMed ID: 18508556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus.
    Ren Z; Ji X; Meng L; Wei Y; Wang T; Feng N; Zheng X; Wang H; Li N; Gao X; Jin H; Zhao Y; Yang S; Qin C; Gao Y; Xia X
    Virus Res; 2015 Mar; 200():9-18. PubMed ID: 25599603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant vaccines for influenza virus.
    Tripp RA; Tompkins SM
    Curr Opin Investig Drugs; 2008 Aug; 9(8):836-45. PubMed ID: 18666031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.